Therapeutic Asset Ratings
153 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ALLOPREGNAN-3.ALPHA.-OL-20-ONE
Parkinson Disease
Roberta Brinton
P1
CC
(40)
Carbamazepine
Parkinson Disease
Cerevel Therapeutics, LLC
P1
CC
(40)
FLORTAUCIPIR
Parkinson Disease
Mayo Clinic
P1
CC
(40)
pdm608
Parkinson Disease
Calibr, a division of Scripps Research
P1
CC
(40)
Selnoflast
Parkinson Disease
Hoffmann-La Roche
P1
CC
(40)
TRN501
Parkinson Disease
SNLD, Ltd.
P1
CC
(40)
Alloex
Parkinson Disease
The Foundation for Orthopaedics and Regenerative Medicine
P1
C
(37)
ams2434
Parkinson Disease
University of Arkansas
P1
C
(37)
Anpd001
Parkinson Disease
Aspen Neuroscience
P1
C
(37)
Autologous Midbrain Dopamine Neurons
Parkinson Disease
Penelope J. Hallett, Ph.D.
P1
C
(37)
Bms-9894923
Parkinson Disease
Allyx Therapeutics
P1
C
(37)
DEXKETOPROFEN
Parkinson Disease
Hasan Kalyoncu University
P1
C
(37)
hl-400
Parkinson Disease
Highlightll Pharmaceutical (USA) LLC
P1
C
(37)
Huc-Msc-Sev-001 Nasal Drops
Parkinson Disease
Xuanwu Hospital, Beijing
P1
C
(37)
HUMAN FAECAL MATTER
Parkinson Disease
Chang Gung Memorial Hospital
P1
C
(37)
Human Fgf-1
Parkinson Disease
Zhittya Genesis Medicine, Inc.
P1
C
(37)
ips101a
Parkinson Disease
Innopeutics Corporation
P1
C
(37)
Lbt-3627
Parkinson Disease
Longevity Biotech Australia Pty Ltd (subsidiary)
P1
C
(37)
ly4006896
Parkinson Disease
Eli Lilly and Company
P1
C
(37)
METAMIZOLE
Parkinson Disease
Hasan Kalyoncu University
P1
C
(37)
NEPENTHE
Parkinson Disease
Hasan Kalyoncu University
P1
C
(37)
nm-101
Parkinson Disease
Neuramedy Co. Ltd.
P1
C
(37)
Stem-Pd
Parkinson Disease
Region Skane
P1
C
(37)
TENOFOVIR DISOPROXIL FUMARATE
Parkinson Disease
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
P1
C
(37)
Clozapine
Parkinson Disease
Ruijin Hospital
Early P1
C
(37)
Showing 101 to 125 of 153 assets
Previous
Page 5 of 7
Next